Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs

Technology appraisal guidance
Reference number: TA225
Published: 22 June 2011

History

Background information

TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: review decision - September 2013 information
TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: Appendix A - decision paper presented to the Institute's Guidance Executive (PDF 226 KB)

Published:

16 September 2013
TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: review proposal - July 2013 information
TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: Appendix A provisional matrix of stakeholders (PDF 42 KB)

Published:

15 July 2013
TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: Appendix B proposal paper presented to the Institute's Guidance Executive (PDF 519 KB)

Published:

15 July 2013
Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: press release information
2011/096 NICE recommends new drug for rheumatoid arthritis (PDF 105 KB)

Published:

06 December 2013

Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: equality impact assessment

Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: equality impact assessment (PDF 73 KB)

Published:

08 July 2011

Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final appraisal determination

Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final appraisal determination information
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final appraisal determination document (PDF 252 KB)

Published:

13 May 2011
Patient Access Scheme
Patient Access Scheme submitted by Merck Sharpe & Dohme (MSD) (PDF 382 KB)

Published:

13 May 2011
Letter from the Department of Health confirming NICE can consider the Patient Access Scheme (PDF 40 KB)

Published:

13 May 2011
Report on the additional data and data requested following the second committee meeting produced by the School of Health and Related Research (ScHARR) (PDF 579 KB)

Published:

13 May 2011
Additional data request
NICE request to the manufacturer for additional data (PDF 131 KB)

Published:

13 May 2011
Manufacturer's response to NICE's request for additional data (PDF 218 KB)

Published:

13 May 2011
Response to request for re-modelling and additional information from Merck Sharp & Dohme (MSD) (PDF 563 KB)

Published:

13 May 2011
Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 495 KB)

Published:

13 May 2011
Report on the additional data requested following the ACD produced by the School of Health and Related Research (ScHARR) (PDF 497 KB)

Published:

13 May 2011
Consultee and commentator comments on the ACD
Merck Sharpe & Dohme (MSD) (PDF 799 KB)

Published:

13 May 2011
British Health Professionals in Rheumatology (PDF 170 KB)

Published:

13 May 2011
National Rheumatoid Arthritis Society (PDF 217 KB)

Published:

13 May 2011
Royal College of Nursing (PDF 60 KB)

Published:

13 May 2011
Royal College of Pathologists (PDF 40 KB)

Published:

13 May 2011
Welsh Assembly Government (PDF 39 KB)

Published:

13 May 2011
Abbott Laboratories (PDF 150 KB)

Published:

13 May 2011
Pfizer (PDF 102 KB)

Published:

13 May 2011
Roche Pharmaceuticals (PDF 136 KB)

Published:

13 May 2011
UCB Pharma (PDF 157 KB)

Published:

13 May 2011

Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: appraisal consultation

Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: appraisal consultation
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: appraisal consultation document information
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: evaluation report
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: pre-meeting briefing (PDF 280 KB)

Published:

22 October 2010
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: evidence review group report (PDF 974 KB)

Published:

22 October 2010
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: clarification
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: manufacturer's response to clarification
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: manufacturer response to first clarification (PDF 1001 KB)

Published:

22 October 2010
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: manufacturer response to follow-up clarification (PDF 312 KB)

Published:

22 October 2010
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: NICE clarification letters
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: NICE follow-up clarification letter (PDF 196 KB)

Published:

22 October 2010
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: NICE clarification letter (PDF 89 KB)

Published:

22 October 2010
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: non-manufacturer submissions
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: submission from National Rheumatoid Arthritis Society (PDF 67 KB)

Published:

22 October 2010
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: submission from British Society for Rheumatology (PDF 181 KB)

Published:

22 October 2010
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: submission from Primary Care Rheumatology Society (PDF 54 KB)

Published:

22 October 2010
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: submission from Royal College of Nursing (PDF 71 KB)

Published:

22 October 2010
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: submission from Royal College of Pathologists (PDF 56 KB)

Published:

22 October 2010
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: submission from NHS Dorset (PDF 106 KB)

Published:

22 October 2010
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: submission from NHS North of Tyne working on behalf of Newcastle and North Tyneside Primary Care Trusts and Northumberland Care Trust (PDF 40 KB)

Published:

22 October 2010
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: submission from NHS Torbay (PDF 326 KB)

Published:

22 October 2010
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: manufacturer submission (PDF 3.3 MB)

Published:

22 October 2010
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: expert written personal statements
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: expert personal statement - Deighton (PDF 76 KB)

Published:

22 October 2010
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: expert personal statement - Moots (PDF 56 KB)

Published:

22 October 2010

Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final matrix

Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final matrix (PDF 38 KB)

Published:

27 September 2010

Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final scope

Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final scope
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: updated final scope April 2010 (PDF 40 KB)

Published:

07 May 2010
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final scope (PDF 40 KB)

Published:

23 March 2009

Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: Institute's response to consultee and commentator comments on the draft scope

Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: Institute's response to consultee and commentator comments on the draft scope
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: Institute's response to consultee and commentator comments on the draft scope (PDF 79 KB)

Published:

07 May 2010
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: Institute's response to consultee and commentator comments on the draft scope (PDF 79 KB)

Published:

23 March 2009

Letter for consultees and commentators on the suspension of this appraisal.

Letter for consultees and commentators on the suspension of this appraisal. (PDF 21 KB)

Published:

03 June 2009

Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: Institute's response to consultee and commentator comments on the provisional matrix

Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: Institute's response to consultee and commentator comments on the provisional matrix (PDF 14 KB)

Published:

23 March 2009

Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: draft scope

Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: draft scope (PDF 41 KB)

Published:

23 March 2009

Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: provisional matrix

Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: provisional matrix (PDF 37 KB)

Published:

23 March 2009